Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

Related Clinical Trial
Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia Efficacy and Safety of Lower-dose Decitabine in Refractory Aplastic Anemia Quantitative MRI of Bone Marrow Fat Fraction in Patients With Trepanobiopsy Avatrombopag Usage in NSAA Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization Retrospective Study of Patients With Severe Aplastic Anemia Who Relapsed After Immunosuppressive Therapy Retrospective Study of Patients With Severe Aplastic Anemia Who Developed High Risk Clonal Evolution With Chromosome 7Abnormalities After Immunosuppressive Therapy REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Investigation of the Cylex® ImmuKnow® Assay Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant Umbilical Cord Blood Transplantation From Unrelated Donors Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study Unrelated Umbilical Cord Blood (UBC)Transplantation New York Blood Center National Cord Blood Program Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis Effects of Aerobic Training and Inspiratory Muscle Training in Patients During Hematopoietic Stem Cell Transplantation A Phase II Study of Umbilical Cord Blood Transplantation Transplants With Unlicensed Preserved Cord Blood Safety Study of Cord Blood Units for Stem Cell Transplants Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. Protection Against Benzene Toxicity Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA Etiology of Blood Dyscrasias: Analysis of the International Agranulocytosis and Aplastic Anemia Study Data Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders King’s Invasive Aspergillosis Study II Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy Aplastic Anemia Epidemiology: Incidence and Case-control Drug Etiology of Aplastic Anemia and Related Dyscrasias hATG+CsA vs hATG+CsA+Eltrombopag for SAA Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA) Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Severe Aplastic Anemia Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA) Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia Multi Center Case Control Study on Multiple Risk Factors of Aplastic Anemia NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) Haploidentical Transplantation in Severe Aplastic Anemia A Description of Bacteria in the Mouths of Patients With Severe Aplastic Anemia Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Patients A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia (SAA) Patient Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin Regimens in Severe Aplastic Anemia Patients A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia Stem Cell Factor Medication for Aplastic Anemia Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome Extended Dosing With Eltrombopag for Severe Aplastic Anemia Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF) Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Aplastic Anemia Stem Cell Mobilization Potential in Patients With Aplastic Anemia in Remission A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia Collection of Blood and Bone Marrow From Patients With Aplastic Anemia for Analysis of Adhesion Molecules, Chemokines and Their Receptors Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia Alefacept in Patients With Relapsed/Refractory Aplastic Anemia Oral Manifestations of Aplastic Anemia The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia. Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA) ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia: Combination Therapy of Severe Aplastic Anemia Comparing Therapies for the Treatment of Severe Aplastic Anemia Mesenchymal Stem Cells Co-transplantation in Alternative Donor Transplantation of Severe Aplastic Anemia. Study of AMG531(Romiplostim) in Patients With Aplastic Anemia Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia Alemtuzumab and Rituximab in Aplastic Anemia Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia Study of Fludarabine + Cyclophosphamide + TBI Conditioning Regimen for Double Units Cord Blood Transplantation(CBT)in Severe Aplastic Anemia(SAA) Safety and Efficacy of Patient’s Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia Ambispective Observational Study to Evaluate the Incidence and Management of Aplastic Anemia in Spain Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia

Brief Title

Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

Official Title

A Randomized Trial of Sirolimus (Rapamune(R)) for Relapse Prevention in Patients With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

Brief Summary

      Background:

      People with severe aplastic anemia (SAA) do not make enough red and white blood cells, and/or
      platelets. Their body's immune system stops the bone marrow from making these cells. The
      treatment cyclosporine leads to better blood counts. But when this treatment is stopped, the
      disease may return in 1 in 3 people. The drug sirolimus may help by suppressing the immune
      system.

      Objective:

      To evaluate and compare the usefulness of sirolimus in preventing aplastic anemia from
      returning after cyclosporine is stopped, compared with stopping cyclosporine alone.

      Eligibility:

      People ages 2 and older with SAA who:

      Have responded to immunosuppressive therapy that includes cyclosporine, and continue to take
      cyclosporine

      Are not taking drugs with hematologic effects

      Design:

      Participants will be screened with:

      Medical history

      Physical exam

      Blood and urine tests

      Bone marrow biopsy: The area above the hipbone will be numbed. A thin needle will remove

      some bone marrow.

      Participants will be randomly assigned to a group. All will stop cyclosporine. Group 1 will
      take sirolimus by mouth at the same time each day for 3 months with close monitoring. Group 2
      will not receive the study drug but will be monitored closely.

      Participants will have clinical tests for the first 3 months:

      Weekly blood test

      Monthly fasting blood test

      For group 1, measurements of sirolimus in the blood every 1 2 weeks

      Participants will have clinic visits at 3 months, 12 months, and annually for 5 years after
      the study starts. They may have another visit if their SAA returns. These will include:

      Blood and urine tests

      Bone marrow biopsy...
    

Detailed Description

      -  Most acquired aplastic anemia ensues from immune-mediated destruction of hematopoietic
           stem and progenitor cells

        -  Immunosuppression is the definitive treatment of patients with acquired aplastic anemia
           who are not candidates for immediate hematopoietic stem cell transplantation.

        -  Horse ATG combined with the calcineurin inhibitor, cyclosporine (CsA), remains standard
           as first-line immunosuppressive therapy (IST).

        -  Hematologic responses to transfusion independence occur in about two thirds of patients
           with standard IST and in 80-90% of patients treated with IST in combination with the
           growth factor eltrombopag.

        -  About 30% to 40% of patients relapse after discontinuation of cyclosporine. Many achieve
           disease control after the reinitiation of CSA, but remain CSA dependent indefinitely.

        -  Evidence from mouse models of bone marrow failure indicates that conversion from
           cyclosporine to the mTOR inhibitor, sirolimus (SRL), results in immune tolerance which
           can endure the eventual withdrawal of SRL.

        -  We hypothesize that CSA to SRL conversion will significantly decrease the relapse rate
           after immunosuppressive therapy for acquired aplastic anemia.

        -  This study will investigate the safety and efficacy of SRL for preventing relapse in
           patients previously treated with IST who remain on CSA. The primary endpoint is rate of
           relapse at 2 years following conversion from CSA to SRL, versus stopping CSA.

        -  Biological sampling of peripheral blood and bone marrow aspirates during treatment will
           be used to investigate changes to lymphocyte phenotypes and cytokine profiles.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

To determine if the rate of relapse at 24 months after CSA discontinuation can be improved by conversion to sirolimus in severeaplastic anemia patients who have responded to IST.

Secondary Outcome

 Safety and tolerability of sirolimus.

Condition

Severe Aplastic Anemia

Intervention

Sirolimus

Study Arms / Comparison Groups

 Sirolimus
Description:  sirolimus

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

118

Start Date

December 19, 2016

Completion Date

August 31, 2023

Primary Completion Date

August 31, 2023

Eligibility Criteria

        -  INCLUSION CRITERIA:

               1. Age greater than or equal to 2 years old

               2. Weight greater than 12 kg

               3. Previous diagnosis of SAA by bone marrow biopsy and cytogenics, treated with
                  lymphodepleting therapy ATG, cyclophosphamide or alemtuzumab that included
                  cyclosporine. The lymphodepleting therapy must have been administered at least 12
                  months prior.

               4. Continuous treatment with cyclosporine for the previous 6 months (excluding minor
                  dose delays not exceeding more than 30 days).

               5. Evidence of a hematologic response to an lymphodepletion-based regimen as
                  evidence of at least two of the following:

          -  Absolute neutrophil count greater than or equal to 500/uL

          -  Platelet count greater than or equal to 20,000/uL (without transfusion support)

          -  Absolute reticulocyte count greater than or equal to 60,000/uL (or hemoglobin 10 gm/dL
             without transfusion support)

        EXCLUSION CRITERIA:

          1. Evidence of relapse of aplastic anemia due to cyclosporine withdrawal during the
             previous 6 months

          2. Prior use of sirolimus or other mTOR inhibitor within 12 weeks of study entry

          3. Myelodysplastic syndrome or acute myeloid leukemia, according to WHO diagnostic
             criteria (if baseline BM consistent with MDS after enrollment, patients will be
             considered ineligible and immediately exit the study, and the subject can be replaced
             with another subject)

          4. Patients that are on CYP3A4 inhibitors and cannot replace these medications with other
             equivalent medications for the period of study: protease inhibitors (ritonavir,
             indinavir, nelfinavir, saquinavir), some macrolide antibiotics (clarithromycin,
             telithromycin, erythromycin), azole anti-fungals (fluconazole, itraconazole,
             ketoconazole), metroclopramide, felodipine, nifedipine, carbamazepine, phenobarbital,
             grapefruit juice and St. John s Wort.

          5. Anaphylactic or hypersensitivity reaction to sirolimus

          6. Patients with infections not adequately responding to appropriate therapy as evidenced
             by persistence of a clear source of infection that, in the view of the investigator,
             would preclude safe treatment with sirolimus.

          7. Current pregnancy, or unwillingness to take oral contraceptives or use the barrier
             methods of birth control or practice abstinence to refrain from pregnancy if of
             childbearing potential during the course of the study 8. Lactating women, due to the
             potentially harmful effects on the nursing child.

        9. Patients who have received live vaccines within the past 30 days

        10. Patients with cancer who are actively receiving chemotherapeutic treatment or who take
        drugs with hematological effects such as thrombopoietin receptor agonists (such as
        eltrombopag), granulocyte-colony stimulating factor or erythroid stimulating agents.

        11. Moribund status such that death within 7 to 10 days is likely. Comorbidities of such
        severity that in the view of the Investigator it would likely preclude the patient's
        ability to tolerate sirolimus.

        12. Inability to understand the investigational nature of the study or to give informed
        consent or without a legally authorized representative or surrogate that can provide
        informed consent.
      

Gender

All

Ages

2 Years - 99 Years

Accepts Healthy Volunteers

No

Contacts

Neal S Young, M.D., (301) 827-2988, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT02979873

Organization ID

170019

Secondary IDs

17-H-0019

Responsible Party

Sponsor

Study Sponsor

National Heart, Lung, and Blood Institute (NHLBI)


Study Sponsor

Neal S Young, M.D., Principal Investigator, National Heart, Lung, and Blood Institute (NHLBI)


Verification Date

September 21, 2021